Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > BUSINESS
BUSINESS
- Burosumab Hits Primary Endpoint in PIII for Adult X-Linked Hypophosphatemia: Kyowa Kirin
April 20, 2017
- “Headquarters Involvement Clear” in Access to Patient Medical Charts by Bayer Sales Reps: Attorney for Whistleblower
April 20, 2017
- Xarelto Issue Morally Questionable, but Does Not Constitute Misleading Ads Banned under Law: MHLW Officials
April 20, 2017
- Japan Vaccine Files New Shingles Vaccine: GSK
April 19, 2017
- Biogen’s Sugino to Lead Amgen Astellas; R&D Head Torii Named Successor
April 19, 2017
- AZ Boosting Field Force Specialization with Move to Business Units: Japan Chief
April 19, 2017
- Fujifilm Completes Bio Production Facility in US, Aiming to Initiate Operations in Early 2018
April 19, 2017
- Ex-Takeda Exec Noguchi Becomes President of Celgene Japan
April 18, 2017
- Boehringer Japan Logs 14 Consecutive Years of Growth in Ethical Drug Sales
April 18, 2017
- Celgene Submits Biz Improvement Plan over Side Effect Reporting Violation
April 18, 2017
- Japan Hemophilia Market Likely to Expand to Nearly 70 Billion Yen in 2024: Fuji Keizai
April 17, 2017
- Takecab Most Promoted Drug in HP Market for 4th Month in February: Anterio
April 17, 2017
- Shionogi Files Japan NDA for Another Shire-Licensed ADHD Med
April 14, 2017
- Takeda Chairman Hasegawa to Retire, Become Adviser in June
April 14, 2017
- Sales Rep and Doctor at Center of Xarelto Survey Scandal Conflict over “Patient Consent”
April 14, 2017
- Novo Japan Chalks Up Record Sales in 2016 on Tresiba, Victoza
April 13, 2017
- Bayer Apologizes for Employees’ “Improper” Involvement in Xarelto Survey, Whistleblower Says He Browsed Charts for over 200 Patients
April 12, 2017
- 1st Herceptin Biosimilar Filed in Japan: Nippon Kayaku
April 12, 2017
- Takeda Strikes Microbiome Deal with Canada’s NuBiyota
April 12, 2017
- Kyorin Gains Rights to Merck’s OAB Med in Asia
April 12, 2017
ページ
Japan’s FY2026 drug pricing reform will, for the first time, apply the “G1” price cut rule for long-listed original biologics…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…